This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Three-Month Efficacy Study in the Treatment of Glaucoma and Ocular Hypertension

Richard E. Bensinger, MD; Edwin U. Keates, MD; John D. Gofman, MD; Gary D. Novack, PhD; Efraim Duzman, MD

Arch Ophthalmol. 1985;103(3):375-378.

Abstract
• The ocular hypotensive effect and the safety of levobunolol hydrochloride (0.5% and 1%) were compared with vehicle in this double-masked study of 42 patients with chronic open-angle glaucoma or ocular hypertension. After a washout of ocular hypotensive medication, patients received one of the three test treatments in both eyes twice daily for three months. Both concentrations of levobunolol produced significant reductions in intraocular pressure, while decreases in vehicle-treated patients were minimal. Over the three-month study period, average pressure reductions were approximately 9.0 mm Hg in patients receiving either concentration of levobunolol and 0.5 mm Hg in patients receiving vehicle. Fewer patients were terminated from the study for inadequately controlled intraocular pressure in the levobunolol groups than in the vehicle group. No patients were terminated for drug-related adverse experiences.

Author Affiliations
From the Pacific Eye Foundation, Seattle (Dr Bensinger), and the Pacific Medical Center of Seattle (Dr Gofman); the Scheie Eye Institute, Philadelphia (Dr Keates); and the University of California and Allergan Pharmaceuticals Inc, Irvine (Drs Novack and Duzman).

Footnotes
Accepted for publication Nov 6, 1984.

Reprint requests to Allergan Pharmaceuticals Inc, 2525 Dupont Dr, Irvine, CA 92715 (Dr Novack).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Randomized Clinical Trials on Medical Treatment of Glaucoma: Are They Appropriate to Guide Clinical Practice?
Rossetti et al.
Arch Ophthalmol 1993;111:96-103.
ABSTRACT  

Apraclonidine: A One-Week Dose-Response Study
Jampel et al.
Arch Ophthalmol 1988;106:1069-1073.
ABSTRACT  

The Safety and Efficacy of Topical 1% ALO 2145 (p-Aminoclonidine Hydrochloride) in Normal Volunteers
Abrams et al.
Arch Ophthalmol 1987;105:1205-1207.
ABSTRACT